ReNeuron Group PLC (LON:RENE)

ReNeuron Group PLC (LON:RENE)


Share Price
249.00 p
Change
-8.5 (-3.30 %)
Market Cap
£79.19 m
Proactive Investors - Run By Investors For Investors

ReNeuron Group PLC RNS Release

Total Voting Rights


RNS Number : 8479A
ReNeuron Group plc
03 June 2019
 

 

 

3 June 2019

AIM: RENE

 

ReNeuron Group plc

 

Total Voting Rights

 

At 31 May 2019, the Company had 31,801,617 ordinary shares in issue, all with voting rights. The Company holds no ordinary shares in treasury. The above figure of 31,801,617 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.

  

ENDS

 

ENQUIRIES:

 

ReNeuron

+44 (0)20 3819 8400

Olav Hellebø, Chief Executive Officer


Michael Hunt, Chief Financial Officer

 


Buchanan

+44 (0) 20 7466 5000

Mark Court, Sophie Wills, Tilly Abraham

 




Stifel Nicolaus Europe Limited

+44 (0) 20 7710 7600

Jonathan Senior, Stewart Wallace, Ben Maddison

(NOMAD and Joint Broker)

 


N+1 Singer

+44 (0) 20 7496 3000

Aubrey Powell, Mark Taylor (Joint Broker)


 

 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa and for disability as a result of stroke.  ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action.  ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
TVRDMGGVLZLGLZM

ReNeuron Group PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use